The initial focus will be on Wound Management Technologies’ major product, CellerateRx®, which is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. CellerateRx’s patented collagen fragments, which are a fraction of the size of the native collagen molecules and particles found in other products, deliver the benefits of collagen to the body immediately.
Wound Management Technologies CEO, Scott Haire, said, “This agreement with Pharma Tech represents an important expansion of our sales activities by opening the strategic Middle East region. Pharma Tech has strong marketing operations and deep distribution channels, which strengthen our expectation for excellent results from this new association.”
About Pharma Technology International, LLC
Pharma Technology International, LLC is a joint venture partnership between BioPharma Technologies, Inc. (a subsidiary of Wound Management Technologies, Inc.) (OTC BB: WNDM) and A&Z Pharmaceutical, LLC, to exclusively license, market, distribute and sell Wound Management Technologies’ line of activated collagen-based products, all FDA cleared as medical devices and for use in the ma nagement of chronic and acute wounds and skin ulcers.
About A&Z Pharmaceutical, LLC
A&Z Pharmaceutical, LLC is a privately held wholesale distributor of pharmaceuticals headquartered in Pittsburgh, PA. Through direct contracts with manufacturers, A&Z provides its customers with top-rated pharmaceuticals and medical products at competitive wholesale prices. Since its inception in 1997, A&Z Pharmaceutical, LLC has been selective in targeting its customers, which include tertiary hospitals, medical institutions, and governmental agencies located in the United States, South America, Europe, and the Middle East. For more information, visit http://www.azpharm.com/html/about.htm.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products. The company’s corporate headquarters are in Fort Worth, Texas. For more information please visit the company's Website at www.celleraterx.com.
Click here for more news from CellerateRX.
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
|
